Healthcare Industry News: estradiol
News Release - February 17, 2006
New Oral Contraceptive Approved by FDAFirst Birth Control Pill to Provide 24 Days of Active Hormonal Therapy
ROCKAWAY, N.J., Feb. 17 (HSMN NewsFeed) -- Warner Chilcott announced today that the U.S. Food and Drug Administration (FDA) has approved its 24-day oral contraceptive, Loestrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), for the prevention of pregnancy. Loestrin 24 Fe ("Loestrin 24") is the first birth-control pill approved in the United States that provides 24 days of active hormonal therapy and four days of iron containing placebo pills.
"This FDA approval is a significant step forward for Warner Chilcott as we continue to sharpen our therapeutic focus on women's health and expand our product portfolio in this area," said Roger Boissonneault, Chief Executive Officer of Warner Chilcott.
Warner Chilcott is a specialty pharmaceutical company focused on two areas: women's healthcare and dermatology.
Source: Warner Chilcott
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.